Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
Clinical trial NCT05084989 · COMPLETED
Trial details
- NCT number
- NCT05084989
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-31
- Primary completion
- 2022-08-18
- Enrollment
- 948
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.